BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24505439)

  • 1. A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.
    Martin PT; Golden B; Okerblom J; Camboni M; Chandrasekharan K; Xu R; Varki A; Flanigan KM; Kornegay JN
    PLoS One; 2014; 9(2):e88226. PubMed ID: 24505439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
    Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
    Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
    Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
    BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies.
    Nguyen F; Cherel Y; Guigand L; Goubault-Leroux I; Wyers M
    J Comp Pathol; 2002; 126(2-3):100-8. PubMed ID: 11944998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures.
    Kornegay JN; Bogan DJ; Bogan JR; Dow JL; Wang J; Fan Z; Liu N; Warsing LC; Grange RW; Ahn M; Balog-Alvarez CJ; Cotten SW; Willis MS; Brinkmeyer-Langford C; Zhu H; Palandra J; Morris CA; Styner MA; Wagner KR
    Skelet Muscle; 2016; 6():14. PubMed ID: 27047655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of dystrophin expression in skeletal muscle is associated with senescence of macrophages and endothelial cells.
    Young LV; Morrison W; Campbell C; Moore EC; Arsenault MG; Dial AG; Ng S; Bellissimo CA; Perry CGR; Ljubicic V; Johnston AP
    Am J Physiol Cell Physiol; 2021 Jul; 321(1):C94-C103. PubMed ID: 33979211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.
    Terrill JR; Duong MN; Turner R; Le Guiner C; Boyatzis A; Kettle AJ; Grounds MD; Arthur PG
    Redox Biol; 2016 Oct; 9():276-286. PubMed ID: 27611888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The golden retriever model of Duchenne muscular dystrophy.
    Kornegay JN
    Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated p21 mRNA level in skeletal muscle of DMD patients and mdx mice indicates either an exhausted satellite cell pool or a higher p21 expression in dystrophin-deficient cells per se.
    Endesfelder S; Krahn A; Kreuzer KA; Lass U; Schmidt CA; Jahrmarkt C; von Moers A; Speer A
    J Mol Med (Berl); 2000; 78(10):569-74. PubMed ID: 11199330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
    Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
    Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
    Guo Y; Petrof BJ; Hussain SN
    Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.